May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- Simulation-based robotic surgery training boosts team confidence, communication
- Perioperative leaders gather at 2025 OR Manager Conference
- CMS launches 6-year model to curb wasteful Medicare spending with AI-driven reviews
- Report: Hospitals can cut anesthesia costs, burnout through tech-driven partnerships
- Study: One in four US healthcare workers faces food insecurity
- Digital decision aid boosts shared decision-making in knee replacement consultations
- CMS narrows surveys to immediate jeopardy, harm during shutdown
- Ambient AI turns burnout relief into 'hard ROI' at Seattle Children’s
- Robotics redefine cardiac surgery with precision, smaller incisions, new frontiers in AI and telesurgery
- Private equity bets big on outpatient cardiology as CMS boosts reimbursements
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement